EP2047867 - Bibliographic data

Last update 06/20/2023
Legal status Invention expirée
Origin Européen
(73)Owner APEIRON BIOLOGICS AG
Campus-Vienna-Biocenter 5
1030 Wien
Autriche
(72)Inventors Crackower, Michael A.
St. Lazare, Quebec J7T 3J8
Canada
Penninger, Joseph M
1130 Vienna
Autriche
(74)Agent Mail recipient
CABINET CURAU
"Le Rose de France" 17, boulevard de Suisse PO Box 54
98000 MONACO
Principauté de Monaco
(21)Application number EP08019249.5
(22)Application date 06/19/2003
(11)Publication number EP2047867
Grant date 05/22/2013
(54)Invention title ACE2 activation for treatment of heart, lung and kidney disease and hypertension
(51)International classification A61K 48/00, C12N 9/64, A61K 38/48, C12N 9/64, A61K 38/48
International classification (before reform) None
Claimed priority (31) Number: 389709 P
(32) Date: 06/19/2002
(33) Country: US
Initial application None
Divisional application None
Expected annuity None
Last annuity Annuity: 20 - Amount: 430€ - Payment date 06/21/2022
Publication BREVETS D'INVENTION DESIGNANT MC DELIVRES PAR l'OEB - bulletin 2013/2, of 06/30/2013
History Publication de la délivrance du brevet européen - Legal date 05/22/2013
Constitution de mandataire pour un dossier - Legal date 08/27/2013
Constitution de mandataire pour un dossier - Legal date 03/03/2016
Expiration de l'invention - Legal date 06/20/2023